Cygnus seeks to use GlucoWatch in children:
This article was originally published in Clinica
Cygnus has filed a marketing application with the US FDA for permission to expand the use of its noninvasive blood glucose monitor, the GlucoWatch Biographer, to include children with diabetes aged between seven and 17 years. The wristwatch-like device, which was approved in the US for use in adults earlier this year, measures glucose in interstitial fluid every 20 minutes, for up to 12 hours. Cygnus, of Redwood City, California, says that around 13,000 children in the US are diagnosed with diabetes annually.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.